CUAMC
AKRO

China Universal Asset Management Company’s Akero Therapeutics AKRO Stock Holding History

China Universal Asset Management Company’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,021
Closed -$666K – 499
2025
Q3 		$666K Sell
14,021
-1,990
-12% -$96.4K 0.06% 216
2025
Q2 		$854K Buy
16,011
+41
+0.3% +$1.86K 0.08% 186
2025
Q1 		$646K Buy
15,970
+1,170
+8% +$49.6K 0.06% 221
2024
Q4 		$412K Buy
14,800
+1,446
+11% +$43.8K 0.04% 268
2024
Q3 		$383K Buy
13,354
+5,230
+64% +$136K 0.04% 247
2024
Q2 		$191K Sell
8,124
-2,676
-25% -$57.2K 0.03% 249
2024
Q1 		$273K Buy
10,800
+4,351
+67% +$105K 0.03% 253
2023
Q4 		$151K Buy
6,449
+5,023
+352% +$99.1K 0.03% 235
2023
Q3 		$72.1K Buy
1,426
+701
+97% +$32.6K 0.02% 215
2023
Q2 		$33.9K Buy
725
+91
+14% +$4.17K 0.01% 229
2023
Q1 		$24.3K Buy
634
+159
+33% +$7.09K 0.01% 202
2022
Q4 		$26K Buy
475
+123
+35% +$5.27K 0.01% 163
2022
Q3 		$12K Buy
+352
New +$5.39K 0.01% 186

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's AKRO Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 14,021 shares — an estimated $666K sold.

China Universal Asset Management Company first reported a position in AKRO in Q3 2022 and held it in 13 quarters. The position peaked at $854K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • China Universal Asset Management Company reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 14,021 Akero Therapeutics shares in Q4 2025, an estimated $666K.
  • China Universal Asset Management Company first reported a position in Akero Therapeutics in Q3 2022 and held it in 13 quarters.
  • China Universal Asset Management Company's Akero Therapeutics position peaked at $854K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.